LivaNova PLC Ordinary Shares (LIVN) Stock Price
LIVNStock
$77.58+43.96%52W
Market Cap$4.27B
P/E61.31x
PEG Ratio0.93
Div yield—
Beta0.93
LIVN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)9.47%
Price vs S&P 500 (4W)0.57%
PEG Ratio0.93
VGM Score63.85
P/E Ratio (Annual)61.31x
LIVN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.09 | $1.26 | +15.13%(+$0.17) | |
| Q1 2026 | $0.90 | $0.98 | +9.30%(+$0.08) | |
| Q4 2025 | $0.81 | $0.86 | +5.56%(+$0.05) | |
| Q3 2025 | $0.92 | $1.11 | +20.38%(+$0.19) | |
| Q2 2025 | $0.87 | $1.05 | +20.31%(+$0.18) |
LIVN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.19
4.12
4.19
4.19
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
LIVNLivaNova PLC Ordinary Shares | C | B | B | 2.9x | 8.2% | 68.1% | 12.5% | $77.58 |
| MDTMedtronic plc | B | C | B | 3.2x | 3.8% | 65.7% | 18.1% | $94.75 |
| ITGRInteger Holdings Corporation | C | C | A | 2.3x | 11.6% | 26.1% | 9.7% | $126.70 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | 3.7x | 88.2% | 58.7% | 12.2% | $70.78 |
| AXGNAxogen, Inc. Common Stock | F | B | B | 8.1x | 14.9% | 74.6% | -11.8% | $34.62 |
| BLFSBioLife Solutions Inc. | F | C | A | 18.4x | 14.9% | 63.9% | 2.9% | $38.61 |
| CNMDCONMED Corporation | B | C | B | 1.0x | 9.8% | 55.8% | 8.0% | $46.72 |
| CBLLCeriBell, Inc. Common Stock | F | A | A | 9.4x | — | 88.9% | -68.6% | $25.04 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | 2.2x | 12.4% | 76.5% | 18.5% | $14.16 |
| CVCapsoVision, Inc. Common Stock | F | D | B | 25.0x | — | 50.9% | -217.1% | $6.53 |
| ELMDElectromed, Inc. | C | B | C | 3.1x | 15.6% | 78.5% | 18.8% | $27.42 |
About LivaNova PLC Ordinary Shares
LivaNova is a UK-based medical-device company specializing in cardiopulmonary and neuromodulation solutions. Its portfolio includes heart-lung machines and oxygenation equipment for cardiac and respiratory support, as well as neuromodulation devices for treatment-resistant epilepsy and depression. The company generates approximately 50% of revenue from the US market, 21% from Europe, and the remainder from other regions.